Twist Bioscience upsized $300M stock offering
Analysis based on 6 articles · First reported Aug 04, 2026 · Last updated Aug 05, 2026
The offering is expected to raise $300 million for Altor BioScience, providing capital for growth initiatives, which may be viewed positively for the company's long-term prospects. However, the dilution from new shares may pressure the stock price in the short term, as reflected in the slight pre-market decline.
Altor BioScience Corporation (Nasdaq: TWST), a mid-cap growth and value biotech company, announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at $96.00 per share. The gross proceeds are expected to be $300.0 million, before underwriting discounts and commissions. The company granted underwriters a 30-day option to purchase up to an additional 468,750 shares. The offering is expected to close on August 6, 2026. Twist intends to use the net proceeds for research and development, manufacturing capacity expansion, product offerings, and general corporate purposes. Goldman Sachs & Co. LLC, William Blair, Leerink Partners, and Guggenheim Partners are acting as joint book-running managers. The offering is being made under an automatic shelf registration statement filed with the United States — United States Securities and Exchange Commission.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard